Details : Imiquimod is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Squamous Intraepithelial Lesions.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 10, 2024
Lead Product(s) : Zalifrelimab,Imiquimod
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Submission of an IND application to U.S. FDA in support of the planned initiation of Phase I clinical study for its anti-CTLA4 antibody, UGN-301 (zalifrelimab), investigational immunotherapy designed for monotherapy and combination therapy in treating lo...
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
March 01, 2022
Lead Product(s) : Zalifrelimab,Imiquimod
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zalifrelimab,Imiquimod
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : The University of Texas MD Anderson Cancer Center
Deal Size : Undisclosed
Deal Type : Collaboration
UroGen And MD And erson Collaborate on Bladder Cancer Treatment Research
Details : The collaboration aims to advance combinatorial intravesical immunotherapy, UGN-201 (imiquimod), a TLR 7/8 agonist and UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, for the treatment of HG-NMIBC.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
January 13, 2021
Lead Product(s) : Zalifrelimab,Imiquimod
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : The University of Texas MD Anderson Cancer Center
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Imiquimod,Hydroxychloroquine Sulphate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Clinical trial of immunomodulators combining Imiquimod and Hydroxychloroquine to prevent and treat early COVID-19 infection.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 04, 2020
Lead Product(s) : Imiquimod,Hydroxychloroquine Sulphate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Imiquimod
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Epicutaneous Cryoimmunotherapy Combined With Pembrolizumab for Cutaneous Metastatic Breast Cancer
Details : Imiquimod is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Breast Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 11, 2019
Lead Product(s) : Imiquimod
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Imiquimod
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Bausch Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Genomic Markers Before and After Treatment of Actinic Keratosis With Imiquimod 3.75% Cream
Details : Imiquimod is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Keratosis, Actinic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 16, 2019
Lead Product(s) : Imiquimod
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Bausch Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Imiquimod is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Intraepithelial Neoplasia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 28, 2017
Radiotherapy or Imiquimod in Complex Lentigo Maligna
Details : Imiquimod is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hutchinson's Melanotic Freckle.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 20, 2015
Lead Product(s) : Imiquimod
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase III
Sponsor : Viatris
Deal Size : Inapplicable
Deal Type : Inapplicable
Imiquimod Treatment of CIN Lesions
Details : Imiquimod is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Uterine Cervical Dysplasia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 31, 2014
Lead Product(s) : Imiquimod
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Sponsor : Viatris
Deal Size : Inapplicable
Deal Type : Inapplicable
Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions
Details : Imiquimod is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Anus Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 12, 2014
Reset All
